← Back to Screener
Collegium Pharmaceutical, Inc. Common Stock (COLL)
Price$33.04
Favorite Metrics
Price vs S&P 500 (26W)-5.06%
Price vs S&P 500 (4W)-15.32%
Market Capitalization$1.05B
P/E Ratio (Annual)16.69x
All Metrics
P/CF (Annual)3.19x
Book Value / Share (Quarterly)$9.51
P/TBV (Annual)11.92x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)18.94%
Cash Flow / Share (Quarterly)$10.33
Price vs S&P 500 (YTD)-31.53%
Gross Margin (TTM)59.35%
Net Profit Margin (TTM)8.05%
EPS (TTM)$1.60
10-Day Avg Trading Volume0.60M
EPS Excl Extra (TTM)$1.60
Revenue Growth (5Y)20.28%
EPS (Annual)$1.58
ROI (Annual)5.66%
Gross Margin (Annual)59.35%
Net Profit Margin (5Y Avg)9.59%
Cash / Share (Quarterly)$12.20
P/E Basic Excl Extra (TTM)16.69x
Revenue Growth QoQ (YoY)12.92%
EPS Growth (5Y)15.77%
P/E Normalized (Annual)16.69x
ROA (Last FY)3.79%
Revenue Growth TTM (YoY)23.62%
EBITD / Share (TTM)$4.42
ROE (5Y Avg)19.62%
Operating Margin (TTM)20.96%
Cash Flow / Share (Annual)$10.33
P/B Ratio3.48x
P/B Ratio (Quarterly)4.85x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)2.08x
Net Interest Coverage (TTM)2.30x
ROA (TTM)3.88%
EPS Growth QoQ (YoY)34.79%
EV / EBITDA (TTM)9.70x
EPS Incl Extra (Annual)$1.58
Current Ratio (Annual)1.57x
Quick Ratio (Quarterly)1.40x
3-Month Avg Trading Volume0.52M
52-Week Price Return21.83%
EV / Free Cash Flow (Annual)4.97x
P/E Incl Extra (TTM)16.69x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$1.72
P/S Ratio (Annual)1.34x
Asset Turnover (Annual)0.47x
52-Week High$50.79
Operating Margin (5Y Avg)16.98%
EPS Excl Extra (Annual)$1.58
CapEx CAGR (5Y)-65.83%
26-Week Price Return-0.51%
Quick Ratio (Annual)1.41x
13-Week Price Return-30.12%
Total Debt / Equity (Annual)2.68x
Current Ratio (Quarterly)1.57x
Enterprise Value$1,627.199
Revenue / Share Growth (5Y)17.42%
Asset Turnover (TTM)0.48x
Book Value / Share Growth (5Y)12.10%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)8.30x
Pretax Margin (Annual)11.87%
Cash / Share (Annual)$12.20
3-Month Return Std Dev37.39%
Gross Margin (5Y Avg)55.45%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)24.02%
EBITDA Interim CAGR (5Y)24.46%
ROE (Last FY)20.84%
Net Interest Coverage (Annual)2.30x
EPS Basic Excl Extra (Annual)$1.58
P/FCF (TTM)3.20x
Receivables Turnover (TTM)3.55x
EV / Free Cash Flow (TTM)4.97x
Total Debt / Equity (Quarterly)2.68x
EPS Incl Extra (TTM)$1.60
Receivables Turnover (Annual)3.55x
ROI (TTM)5.82%
P/S Ratio (TTM)1.34x
Pretax Margin (5Y Avg)6.68%
Revenue / Share (Annual)$19.66
Tangible BV / Share (Annual)$1.72
Forward P/E4.53x
Free OCF CAGR (5Y)56.88%
Price vs S&P 500 (52W)-8.69%
P/E Ratio (TTM)16.69x
EPS Growth TTM (YoY)-5.88%
Year-to-Date Return-28.64%
5-Day Price Return-6.85%
EPS Normalized (Annual)$1.58
ROA (5Y Avg)4.07%
Net Profit Margin (Annual)8.05%
Month-to-Date Return-0.09%
Cash Flow / Share (TTM)$4.22
EBITD / Share (Annual)$4.23
EPS Growth (3Y)-0.62%
Operating Margin (Annual)20.96%
LT Debt / Equity (Annual)2.59x
P/CF (TTM)3.19x
ROI (5Y Avg)6.13%
P/E Excl Extra (TTM)16.69x
LT Debt / Equity (Quarterly)2.59x
EPS Basic Excl Extra (TTM)$1.60
P/TBV (Quarterly)11.92x
P/B Ratio (Annual)4.85x
Inventory Turnover (TTM)8.30x
Pretax Margin (TTM)11.87%
Book Value / Share (Annual)$9.51
Price vs S&P 500 (13W)-31.26%
Net Margin Growth (5Y)-1.43%
Beta0.78x
P/FCF (Annual)3.20x
Revenue / Share (TTM)$19.20
ROE (TTM)24.11%
52-Week Low$25.86
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.08
4.08
4.08
4.08
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
COLLCollegium Pharmaceutical, Inc. Common Stock | 1.34x | 23.62% | 59.35% | 15.77% | $33.04 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Collegium Pharmaceutical is a biopharmaceutical company that develops and commercializes treatments for ADHD and moderate to severe pain in the United States. Its marketed product portfolio includes Jornay PM for ADHD, Belbuca and Xtampza ER for pain management, the Nucynta line (Nucynta ER and IR), and Symproic.